Oral Aleniglipron Reduced Weight at 36 Weeks - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

  • 1

    Aleniglipron reduced body weight by 9% to 12% at 36 weeks in adults with obesity or overweight, compared to 1% with placebo.

  • 2

    The ACCESS trial involved 230 patients, aged 18 to 79 years, with a mean BMI of 39.5 kg/m² and a mean weight of 114.8 kg.

  • 3

    Gastrointestinal adverse events were common, occurring in 79% to 89% of aleniglipron-treated patients, with nausea being the most frequent.

  • 4

    At week 56, mean weight loss was 13.3%, 16.2%, and 15.3% for patients initially assigned to 45 mg, 90 mg, and 120 mg, respectively.

  • 5

    The study had limitations, including a predominantly White population and lower female participation compared to other obesity trials.

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

FDA authorizes continuous ketone monitor

Patients aged 2 years and older with diabetes are eligible to use the wearable.

May Lower RFR Signal Repeat Revascularization?

Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.